ethamolin and Mouth-Diseases

The objective of this study was to report and discuss the results from treatment of benign oral vascular lesions with ethanolamine oleate.. Twenty-seven patients with 30 examples of oral vascular malformation, hemangioma, or varix were treated with intralesional injections of 1.25% or 2.5% ethanolamine oleate at an interval of 15 days between each application. The lesions were divided into 2 categories: (1) lesions of 20 mm or less and (2) those greater than 20 mm. Subsequently, the Mann-Whitney test was used a means of statistical analysis.. Although the number of injections varied from patient to patient, all lesions responded to the treatment, showing total clinical regression. Lesions of 20 mm or less needed a lesser number of applications than those greater than 20 mm (P < .05).. Ethanolamine oleate is a 100% effective sclerosant agent for treatment of benign oral vascular lesions. In this study, no difference was found between the 2 concentrations applied.

Topics: Adolescent; Adult; Aged; Arteriovenous Malformations; Child; Female; Hemangioma; Humans; Injections, Intralesional; Male; Middle Aged; Mouth Diseases; Mouth Neoplasms; Neoplasms, Vascular Tissue; Oleic Acids; Sclerosing Solutions; Sclerotherapy; Statistics, Nonparametric; Varicose Veins; Vascular Diseases

The aim of this study was to evaluate the efficacy of ethanolamine oleate (EO) sclerotherapy in the treatment of peripheral giant cell granuloma.. This study included 24 patients presenting with PGCGs greater than 2 cm in diameter. Definitive diagnosis was confirmed after histopathologic examination of incisional biopsy specimens. EO sclerotherapy at a concentration of 2.5% was injected into each lesion once a week. Repeated injections were performed if needed. The treatment response was recorded as complete remission, moderate response, or no change.. This study involved 11 male and 13 female patients, ranging in age from 9 to 70 years; the average age was 45.3 years. The mandible (75%) was involved more than the maxilla. PGCGs occurred posteriorly (62.5%) more than anteriorly. The number of injection sessions was 57, with an average of 2.4 sessions per lesion. Clinical improvement was seen in 23 patients: complete remission in 20 (83.3%) and moderate improvement in 3 (12.5%). No clinical improvement occurred in 1 patient (4.2%).. EO injection offers an alternative to conventional methods for the treatment of PGCG. The technique is straightforward, safe, and cost-effective with a high success rate.

Topics: Adolescent; Adult; Aged; Child; Female; Granuloma, Giant Cell; Humans; Injections, Intralesional; Male; Middle Aged; Mouth Diseases; Oleic Acids; Sclerosing Solutions; Sclerotherapy; Treatment Outcome; Young Adult

We reported a case of varicosities in the buccal mucosa treated with sclerotherapy. The sclerosant agent used was the monoethanolamine oleate. After three sessions the lesions disappeared and the patient is follow-up.

Topics: Endothelium, Vascular; Female; Humans; Injections, Intravenous; Middle Aged; Mouth Diseases; Mouth Mucosa; Oleic Acids; Sclerosing Solutions; Varicose Veins